Oncology Sponsored The Compound Effect: Real-World Evidence for the Impact of C... In a new report, Medscape Medical Affairs explores the question of whether a coordinated programme drives more real-world behaviour change.
Digital Sponsored The hardest part of becoming an AI-first company: It’s not t... Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.
R&D Why every healthcare breakthrough creates a new education ch... Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.
Sales & Marketing Pharma is marketing to the wrong mind On the benefits of instinctive marketing, over either rational or emotional.
R&D Results, reality, and recalibration: Unpacking AI hype at SC... SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.